Clinical Trials Logo

Clinical Trial Summary

To pilot early community client-led ART (anti-retroviral therapy) delivery (CCLAD) in Nakivale Refugee Settlement in Uganda and assess the feasibility and acceptability of this intervention in this setting.


Clinical Trial Description

Adults accessing routine HIV testing in Nakivale Refugee Settlement will be invited to participate. The study population will include adult refugees and Ugandan nationals of all genders older than 18 years of age. Pregnant women will be invited but Maternal Health Clinic will determine if they participate. Those that test positive for HIV will be invited to participate in the Early Community Client-Led ART Delivery group intervention. Individuals will be offered research participation which will include an intake survey, an HIV test, and the option to participate in early community client-led ART delivery (early CCLAD) groups if diagnosed with HIV. Those interested in participating will have a consent form read aloud to them by a Research Assistant before being tested for HIV. Consent forms will be available in 4 languages: Runyankore, Kinyarwanda, Kiswahili and English, and will be read by multi-lingual Research Assistants. These individuals will be told at the outset that they can alternatively access free HIV testing at the outpatient department clinic if they prefer to not participate in any aspect of the research. After consent but prior to HIV testing, the investigators will conduct a baseline survey. This will include collection of contact information, demographic information, physical assessment, migration patterns, HIV testing history, perceived stigma, screening for mental disorders, and assessment of social support. Like the consent process, the survey will be available in 4 languages: Runyankore, Kinyarwanda, Kiswahili or English, and will be read aloud to participants with responses entered directly into a passcode-protected electronic tablet. The first meeting of each Early CCLAD group will include an HIV clinic clinician. The first meeting is the one time in the intervention where participants will be compensated for their transportation to the clinic or to the meeting site (20,000 USH will be provided for each participant who attends this meeting). The HIV clinician, who will have been trained in the Early CCLAD group intervention, will help individuals in the group to understand their roles and responsibilities. The group will work together to plan future meeting dates and locations. The participants will decide if they would like to support the person responsible for picking up the ART each month (e.g. money, transportation, childcare, food). The participants will specify which dates they will be responsible to attend HIV clinic and pick up ART for the group. They will discern if they would like to identify a connecting activity to be integrated into their group (e.g. exercise, faith, livelihood, craft). The participant group will select a Team Leader to coordinate communication between the group and the healthcare facility. Finally, an important part of this first meeting is that the HIV clinician will conduct a standard comprehensive clinical exam and will refer each person/participant for any necessary laboratory testing. Monthly "Early CCLAD" meetings: The "Early CCLAD" intervention will require monthly group meetings. This is intentionally more frequent than is suggested in the Ugandan Ministry of Health guidelines (which recommends visits every 3 months) as this intervention will occur at the time of diagnosis rather than when a person is deemed "stable" in care. Before the designated individual goes to clinic in any given month, they will be responsible for connecting with each group member to ask about how they are feeling and to see if they have any questions to ask of the HIV clinic staff. That individual will then attend HIV clinic and communicate about the status of each group member. They will collect information from the clinic and pre-packed ART for each group member. The "Early CCLAD" group will then meet at their predetermined location so that the individual who attended clinic can share information from the clinic and can distribute the ART to each person in the group. If a participant misses a CCLAD group, they can present to the HIV clinic to pick up their ART refill if a member of the group cannot arrange delivery or pickup. Additional clinic attendance: All participants assigned to an "Early CCLAD" group will be expected to attend HIV clinic in person twice yearly for a clinical evaluation and a viral load check. The HIV clinician will work with the team to decide if they prefer their twice annual HIV clinic visits on the same day but individually, on the same day as a group, or individually on different schedules from others in the group. Additionally, individuals will attend clinic in person when they do not feel well, when they have any questions they prefer to ask the clinicians directly, when additional laboratory testing is required, and when requested by HIV clinic staff to optimize their medical care. In cases where the participants are deemed clinically unstable and are in need of regular clinical follow up (e.g. develops an opportunistic infection, develops other co-morbidity, has a viral load > 1,000 copies/mL), clients will be asked to attend the clinic monthly with the rotating group member collecting group ART refill or to step in as the group member responsible for attending clinic that month. Individuals "Up referred" by HIV clinic staff to monthly HIV clinic visits should still participate in the "Early CCLAD" groups to receive psychosocial support and other benefits of community group care. Option to stop the "Early CCLAD" group at any time: Participants can opt to stop Early CCLAD participation at any time. If willing, they will be asked to participate in a brief exit interview so the investigators can better understand what aspects of the intervention were acceptable or not acceptable to them. "Early CCLAD" groups and HIV clinic connectedness: To ensure the Early CCLAD intervention participants remain well integrated into HIV clinic, the research staff will meet regularly with the HIV clinic staff to update them on the intervention and to discuss specific problems and specific individuals needing specialized care. Additionally, efforts will be made so that participant HIV clinic files and pre-packed medications are ready for the visit of the individual Early CCLAD group member each month. Finally, participants will be reminded frequently that they are expected and welcome to attend clinic when they do not feel well or when they have any questions or needs that are not being met through group care. Follow-up data collection: Early CCLAD group participants will be given components of the intake survey (i.e. to assess mental health screening, perceived stigma, and social support) again 6-months after they began participation in the intervention. Some of this may occur in an interview setting which is recorded and then later transcribed. Additionally, data will be collected to assess retention in group care, ART medication pick-up, and HIV clinic outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04736316
Study type Interventional
Source University of Washington
Contact
Status Completed
Phase N/A
Start date June 29, 2020
Completion date March 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03661203 - Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
Completed NCT00381212 - A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. Phase 1/Phase 2
Not yet recruiting NCT05983536 - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Recruiting NCT04832477 - Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US N/A
Active, not recruiting NCT04044586 - HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
Completed NCT03218839 - Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males N/A
Active, not recruiting NCT00797030 - Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Phase 4
Recruiting NCT04088916 - Proviral DNA as a Target for HIV-1 Resistance Analysis
Completed NCT03367130 - Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal N/A
Completed NCT04849767 - National Survey About Trajectory and Life Conditions of HIV Trans People in France
Completed NCT05674682 - Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study N/A
Recruiting NCT05174234 - Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
Completed NCT00130819 - Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants Phase 2
Active, not recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT03858478 - Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST Phase 4
Completed NCT02154971 - Assessment of Age-related Hearing Loss in HIV-1 Patients
Recruiting NCT03311945 - Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Phase 3
Recruiting NCT03333083 - Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Phase 3
Recruiting NCT03795415 - ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
Completed NCT01813292 - Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine N/A